Tarsus Pharmaceuticals (TARS) Institutional Ownership
13F filers reported holding 8.1% of Tarsus Pharmaceuticals (TARS) shares as of Sep 30, 2026, across 92 filers.
- Held by 13F filers
- 8.1%
- Sep 30, 2026
- 13F filers
- 92
- quarter ended Sep 30, 2026
- 13F value
- $312.7M
- 4.0M shares
- Quarter's fund flow
- Mild accumulation
- 13 new · 12 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Disposed · Open-market sale | 5,387 | $85.00 | ↗ |
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Disposed · Open-market sale | 5,386 | $90.00 | ↗ |
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Disposed · Open-market sale | 1,590 | $85.00 | ↗ |
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Disposed · Open-market sale | 1,590 | $90.00 | ↗ |
| Sep 4, 2026 | Azamian Bobak R. | President/CEO and Board Chair | Disposed · Open-market sale | 7,100 | $90.27 | ↗ |
| Sep 4, 2026 | Azamian Bobak R. | President/CEO and Board Chair | Disposed · Open-market sale | 2,900 | $91.27 | ↗ |
| Sep 4, 2026 | Neervannan Seshadri | Chief Operating Officer | Disposed · Open-market sale | 4,564 | $85.00 | ↗ |
| Sep 2, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Disposed · Open-market sale | 5,387 | $80.00 | ↗ |
| Sep 2, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Disposed · Open-market sale | 1,590 | $80.00 | ↗ |
| Sep 2, 2026 | Azamian Bobak R. | President/CEO and Board Chair | Disposed · Open-market sale | 10,000 | $80.06 | ↗ |
| Sep 1, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Disposed · Open-market sale | 4,601 | $73.86 | ↗ |
| Jun 25, 2026 | Goodrich Katherine | director | Acquired · Grant / award | 3,837Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Goodrich Katherine | director | Acquired · Grant / award | 2,417Restricted Stock Units | — | ↗ |
| Jun 25, 2026 | Goldberg Andrew D. | director | Acquired · Grant / award | 3,837Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Goldberg Andrew D. | director | Acquired · Grant / award | 2,417Restricted Stock Units | — | ↗ |
| Jun 25, 2026 | Morrison Scott W | director | Acquired · Grant / award | 3,837Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Morrison Scott W | director | Acquired · Grant / award | 2,417Restricted Stock Units | — | ↗ |
| Jun 25, 2026 | CHAUDHURI BHASKAR | director | Acquired · Grant / award | 3,837Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | CHAUDHURI BHASKAR | director | Acquired · Grant / award | 2,417Restricted Stock Units | — | ↗ |
| Jun 25, 2026 | LINK WILLIAM J PHD | director | Acquired · Grant / award | 3,837Stock Option (right to buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Tarsus Pharmaceuticals do institutions hold?
13F filers reported holding 8.1% of Tarsus Pharmaceuticals' shares as of Sep 30, 2026, across 92 filers.
How many 13F filers hold Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals was held by 92 13F filers as of Sep 30, 2026.
Not investment advice.

